Biopharm Enters Global Commercialization 2.0 Era with Platform-Based Expansion and Strengthened Oncology Portfolio

Article source：Kexing BiopharmAug 12,2025View： 74

Kexing Biopharm has officially entered a new chapter in its global growth journey, transitioning from a traditional export model to a comprehensive, platform-driven globalization strategy. This evolution marks the arrival of what the company defines as its Global Commercialization 2.0 Era — characterized by a forward-looking approach that integrates global product sourcing, cross-border partnerships, and expansive international coverage.

In recent years, Kexing Biopharm has transformed its business model from one focused solely on exporting proprietary products to an open, collaborative platform that identifies, develops, and commercializes promising therapies from around the world. This “Innovation + International" strategic shift allows the company to leverage both its own innovation and the innovations of global partners.

Through active engagement with a broad network of domestic and international pharmaceutical innovators, Kexing Biopharm has forged partnerships that expand its product pipeline across several high-value therapeutic areas.

These include antivirus, antitumor, Immunosuppressant, and Metabolic Diseases, with antitumor emerging as a particularly strategic focus. The company has built a robust and well-structured oncology product matrix, enabling it to address a wide range of solid tumors and hematologic cancers with precision-targeted therapies and combination treatment strategies.

“We are no longer simply bringing Chinese biopharma innovation to the world — we are building a globally integrated commercialization platform,” said a company spokesperson. “This means not only offering our own products internationally, but also acting as a gateway for global biotech breakthroughs to reach broader markets, supported by our regulatory expertise, commercial infrastructure, and clinical development experience.”

Kexing Biopharm’s global platform model emphasizes agility, scalability, and long-term collaboration. By aligning with top-tier R&D institutions, biotech startups, and established pharmaceutical companies, the company is creating a value network capable of accelerating drug development and market entry, especially in regions with underserved patient populations.

The company's progress in the antitumor sector exemplifies this platform-based approach. With a balanced portfolio that spans immune checkpoint inhibitors, targeted therapies, and biologics. Kexing is positioned to deliver impactful treatments across multiple cancer indications. Its strategic focus is on solid tumors such as breast and lung cancers, as well as hematologic malignancies.

Looking ahead, Kexing Biopharm will continue to expand its international footprint through licensing, joint ventures, and co-development opportunities. Its goal is clear: to become a global bridge between innovation and access — delivering high-quality, affordable, and life-changing therapies to patients worldwide.